BR0214403A - Composições farmacêuticas compreendendo metformina e glibenclamida para o tratamento de diabetes melittus tipo ii - Google Patents

Composições farmacêuticas compreendendo metformina e glibenclamida para o tratamento de diabetes melittus tipo ii

Info

Publication number
BR0214403A
BR0214403A BR0214403-4A BR0214403A BR0214403A BR 0214403 A BR0214403 A BR 0214403A BR 0214403 A BR0214403 A BR 0214403A BR 0214403 A BR0214403 A BR 0214403A
Authority
BR
Brazil
Prior art keywords
treatment
type
pharmaceutical compositions
metformin
diabetes mellitus
Prior art date
Application number
BR0214403-4A
Other languages
English (en)
Inventor
Tosetti Alessandro
Guiducci Mauro
Viti Giovani
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11442301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of BR0214403A publication Critical patent/BR0214403A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS COMPREENDENDO METFORMINA E GLIBENCLAMIDA PARA O TRATAMENTO DE DIABETES MELITTUS TIPO II". São descritas composições farmacêuticas administráveis oralmente na forma de tabletes, compreendendo glibenclamida e metformina, ou sais farmaceuticamente aceitáveis destas, como ingredientes ativos, mantidas separadas entre si dentro da mesma composição, para o tratamento de diabetes mellitus tipo II.
BR0214403-4A 2001-11-29 2002-11-29 Composições farmacêuticas compreendendo metformina e glibenclamida para o tratamento de diabetes melittus tipo ii BR0214403A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001FI000230A ITFI20010230A1 (it) 2001-11-29 2001-11-29 Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
PCT/EP2002/013497 WO2003045355A1 (en) 2001-11-29 2002-11-29 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus

Publications (1)

Publication Number Publication Date
BR0214403A true BR0214403A (pt) 2004-10-19

Family

ID=11442301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214403-4A BR0214403A (pt) 2001-11-29 2002-11-29 Composições farmacêuticas compreendendo metformina e glibenclamida para o tratamento de diabetes melittus tipo ii

Country Status (39)

Country Link
US (1) US20050053661A1 (pt)
EP (1) EP1458364B1 (pt)
JP (1) JP4474162B2 (pt)
KR (1) KR20040079898A (pt)
CN (1) CN1596103B (pt)
AR (1) AR037407A1 (pt)
AT (1) ATE387190T1 (pt)
AU (1) AU2002358061B2 (pt)
BR (1) BR0214403A (pt)
CA (1) CA2466677A1 (pt)
CO (1) CO5590906A2 (pt)
CY (1) CY1107966T1 (pt)
DE (1) DE60225331T2 (pt)
DK (1) DK1458364T3 (pt)
EA (1) EA006766B1 (pt)
EG (1) EG24124A (pt)
ES (1) ES2302862T3 (pt)
HN (1) HN2002000341A (pt)
HR (1) HRP20040501A2 (pt)
HU (1) HUP0402154A3 (pt)
IL (1) IL162143A0 (pt)
IT (1) ITFI20010230A1 (pt)
MA (1) MA27087A1 (pt)
MX (1) MXPA04004974A (pt)
MY (1) MY141243A (pt)
NO (1) NO20042713L (pt)
NZ (1) NZ533779A (pt)
PA (1) PA8559801A1 (pt)
PE (1) PE20030580A1 (pt)
PL (1) PL206016B1 (pt)
PT (1) PT1458364E (pt)
RS (1) RS50937B (pt)
SI (1) SI1458364T1 (pt)
SV (1) SV2004001415A (pt)
TN (1) TNSN04095A1 (pt)
UA (1) UA81615C2 (pt)
UY (1) UY27549A1 (pt)
WO (1) WO2003045355A1 (pt)
ZA (1) ZA200404880B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725833A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
RU2398572C1 (ru) * 2009-05-18 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных сахарным диабетом 2 типа
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
RU2483717C2 (ru) * 2010-11-22 2013-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения диабета (варианты)
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
KR20170083071A (ko) 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
KR101750690B1 (ko) * 2015-10-28 2017-06-27 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
CN105596339A (zh) * 2015-12-23 2016-05-25 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方组合物及制备方法
LT3804714T (lt) 2018-05-31 2025-03-10 Hua Medicine (Shanghai) Ltd. Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas
CN110128305A (zh) * 2019-05-10 2019-08-16 天津大学 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
JP2021120357A (ja) * 2020-01-30 2021-08-19 サンノーバ株式会社 錠剤
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2347531A1 (de) 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2725833A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system

Also Published As

Publication number Publication date
CO5590906A2 (es) 2005-12-30
EG24124A (en) 2008-07-07
PL206016B1 (pl) 2010-06-30
IL162143A0 (en) 2005-11-20
EP1458364B1 (en) 2008-02-27
NZ533779A (en) 2007-02-23
ES2302862T3 (es) 2008-08-01
CN1596103A (zh) 2005-03-16
PE20030580A1 (es) 2003-09-05
DK1458364T3 (da) 2008-06-23
MY141243A (en) 2010-03-31
CN1596103B (zh) 2010-06-16
PT1458364E (pt) 2008-05-26
EA006766B1 (ru) 2006-04-28
RS50937B (sr) 2010-08-31
EA200400664A1 (ru) 2004-10-28
CY1107966T1 (el) 2013-09-04
HUP0402154A3 (en) 2008-04-28
JP4474162B2 (ja) 2010-06-02
HK1069974A1 (en) 2005-06-10
AU2002358061B2 (en) 2007-01-11
NO20042713L (no) 2004-07-16
AR037407A1 (es) 2004-11-10
SV2004001415A (es) 2004-05-07
EP1458364A1 (en) 2004-09-22
UY27549A1 (es) 2003-06-30
UA81615C2 (ru) 2008-01-25
TNSN04095A1 (en) 2006-06-01
CA2466677A1 (en) 2003-06-05
DE60225331D1 (de) 2008-04-10
PA8559801A1 (es) 2003-06-30
DE60225331T2 (de) 2009-02-26
HN2002000341A (es) 2009-12-07
AU2002358061A1 (en) 2003-06-10
SI1458364T1 (sl) 2008-08-31
US20050053661A1 (en) 2005-03-10
MA27087A1 (fr) 2004-12-20
ITFI20010230A1 (it) 2003-05-29
MXPA04004974A (es) 2004-08-11
JP2005518360A (ja) 2005-06-23
HUP0402154A2 (hu) 2005-02-28
KR20040079898A (ko) 2004-09-16
WO2003045355A1 (en) 2003-06-05
ZA200404880B (en) 2005-07-29
PL369851A1 (en) 2005-05-02
RS47304A (sr) 2006-10-27
ATE387190T1 (de) 2008-03-15
HRP20040501A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
CY1107966T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
AR037256A1 (es) Forma de dosificacion de liberacion controlada dual
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
SE9901573D0 (sv) New compounds
BR9908702A (pt) Composto, processos para inibir sìntese de óxido nìtrico em um paciente, para inibir seletivamente sìntese de óxido nìtrico produzido pela no sintase indutìvel no óxido nìtrico produzido pelas formas constitutivas de no sintase em um paciente e para diminuir nìveis de óxido nìtrico em um paciente, e, composição farmacêutica
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
SE0002476D0 (sv) New compounds
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
ATE241980T1 (de) Neue inhalationspräparate enthaltend cr 2039 (andolast)
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
SE9901572D0 (sv) New compounds
GT199900171A (es) Concentrado oral de sertralina.
AR046665A1 (es) Formulaciones orales de desoxipeganina y sus usos
AR022338A1 (es) Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
BR0011845A (pt) Complexo farmacêutico
AR034012A1 (es) Compuestos peptidicos, las composiciones farmaceuticas que las contienen y el uso de las mismas para la preparacion de medicamentos
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9AANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.